Roger Cady, MD

Roger Cady has over 40 years of clinical and drug development experience in headache medicine and migraine therapeutics. He has served as Chief Medical Officer of Slate Medicines since its founding. Prior to Slate, Dr. Cady most recently served as Vice President of Neurology at Alder Biopharmaceuticals and H. Lundbeck A/S following their acquisition of Alder, where he was instrumental in the clinical development, FDA approval, and post-approval advancement of Vyepti (eptinezumab). He has authored over 200 peer-reviewed articles, books, and chapters on migraine treatment, including the pivotal study on sumatriptan, and founded the Headache Care Center, the Primary Care Network, and Clinvest, a research network that has conducted over 600 clinical trials. Dr. Cady earned his MD degree from Mayo Medical School.